Asthma
Conditions
Interventions
cough variant asthma:Observation study
classic asthma:Observation study
chest tightness variant asthma:Observation study
Sponsors
Guangzhou Institute of Respiratory Health
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. outpatients, with age from 18 to 70 years old; 2. Newly diagnosed as classic asthma (mild to moderate), CVA, CTVA based on symptom and confirm by pulmonary function test according to China asthma guideline 2016 and China cough guideline (2015). Pulmonary function test must meet one of the following three, suggesting a variable airflow limitation and as a basis for lung function diagnosis of asthma: (1)Positive of bronchial provocation test; (2) Positive of bronchodilation test (both FEV1 increased> 12% and FEV1 absolute increase> 200 ml after inhalation of bronchodilator); (3) Average peak expiratory flow (PEF) in day and night time variation rate =10% within continuous 7 days or weekly variation rate > 20%; 3. Sign (or their legally-acceptable representatives must sign) and date the informed consent form indicating that they understand the purpose of and procedure required for the study and are willing to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Participated in any interventional clinical trial during the last 30 days; 2. Associated with a clear history of lung diseases such as COPD, bronchiectasis, pulmonary infection, pulmonary interstitial disease, pulmonary hypertension, etc; Or combined with other systems severe illness like cardiovascular, metabolic, immunological, neurological, urinary and blood diseases which may affect the normal conduct of this study; 3. A abuse history of alcohol or narcotic drug, or have a mental history, confrontation personality, adverse motives, suspicious or other emotional or intellectual problems that may affect the informed validity of the study. 4. With A history of upper respiratory tract infection acute exacerbation within 4 weeks before enrolment; 5.Routinely treated for asthma within 4 weeks before enrolment. (Including but not limited to oral or inhaled hormones, leukotriene receptor antagonists, antihistamines, etc.); 6. Clinical abnormalities associated with symptoms in chest radiology; 7. Not suitable for study observation judged by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ACT score;VAS score;LCQ score;Improve cough score;Improved ACQ score;Self-Rating Anxiety Scale ;Self-rating depression scale;Induced sputum;Lung function;FeNO; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total IgE;specific IgE; | — |
Countries
China
Contacts
Public ContactRongcheng Chen, Kefang Lai, Huahao Shen
Guangzhou Institute of Respiratory Health
Outcome results
None listed